NeoManna

Company Overview

Snapshot

Founded in January 2022 by Amir Barzilay, NeoManna operates with 1–10 employees. The company has secured funding across one round from one investor, AgChimedes Group. NeoManna is focused on developing novel, natural antimicrobial and anti-inflammatory products to combat antibiotic overuse in animal health.

Business overview

NeoManna specializes in developing, manufacturing, and selling natural antimicrobial and anti-inflammatory products designed to address the global challenge of antimicrobial resistance (AMR). The company's core technology leverages groundbreaking R&D in Black Soldier Fly (BSF) originated bioactives, which are incorporated into both liquid and solid animal nutrition. NeoManna serves the livestock, aquaculture, and companion animal markets, aiming to reduce production costs, improve EBITDA, and safeguard the global food value chain by providing alternatives to traditional antibiotics. The company operates within the Agriculture & Food Technologies sector, with a focus on sustainable farming and clean industry tech.

Company Intelligence Q&A

What is NeoManna's primary focus?

NeoManna is focused on addressing the global challenges and pitfalls of Anti-Microbial Resistance (AMR) by developing, manufacturing, and selling novel, natural anti-microbial and anti-inflammatory products for animal health.

Who are the founders of NeoManna?

NeoManna was co-founded by Amir Barzilay.

What is NeoManna's core technology?

NeoManna utilizes groundbreaking R&D in Black Soldier Fly (BSF) originated bioactives to create high-volume, competitively priced modified BSF ingredients for animal nutrition.

Which markets does NeoManna serve?

NeoManna's products are designed for livestock, aquaculture, and companion animals, aiming to reduce antibiotic overuse in these sectors.

What is NeoManna's business model?

NeoManna operates on a B2B business model, providing its innovative solutions to other businesses within the animal health and nutrition industry.